Serum IL-12p40: A novel biomarker for early prediction of minimal change disease relapse following glucocorticoids therapy.
Serum IL-12p40: A novel biomarker for early prediction of minimal change disease relapse following glucocorticoids therapy.
复制标题
血清 IL-12p40：一种用于早期预测糖皮质激素治疗后微小病变复发的新型生物标志物
DOI：
10.3389/fmed.2022.922193
复制
发表时间：
2022
影响因子：
3.9
通讯作者：
中科院分区：
文献类型：
--
作者：
微小病变病（MCD）复发率高，但目前尚无生物标志物可预测其复发。为此，本研究旨在确定潜在的血清细胞因子作为预测MCD复发风险的有价值的生物标志物。采用Raybiotech 440细胞因子抗体芯片检测8例复发、8例糖皮质激素治疗后未复发MCD患者和8例健康对照者的血清标本。采用酶联免疫吸附试验（ELISA）对29例非复发和35例复发MCD患者的血清样本进行了差异表达细胞因子的确认。该研究使用受试者工作特征（ROC）曲线分析来研究血清生物标志物预测MCD复发的灵敏度和特异性。复发组血清IL-12 p40水平显著升高。IL-12 p40的ROC曲线下面积（AUC）为0.727（95%CI：0.597-0.856; P < 0.01）。对IL-12处理的小鼠足细胞和对照组进行的RNA测序分析和qPCR测定显示，在前一组中，足细胞损伤基因的表达增加，例如结缔组织生长因子（CTGF）、基质金属肽酶9（MMP 9）、分泌型磷蛋白1（SPP 1）和环氧合酶-2（考克斯-2）。IL-12 p40可能作为预测糖皮质激素治疗后MCD复发风险的新生物标志物，并且可能参与MCD的发病机制和复发。
Minimal change disease (MCD) has a high recurrence rate, but currently, no biomarker can predict its recurrence. To this end, this study aimed at identifying potential serum cytokines as valuable biomarkers for predicting the risk of MCD recurrence. Raybiotech 440 cytokine antibody microarray was used to detect the serum samples of eight relapsed, eight non-relapsed MCD patients after glucocorticoid treatment, and eight healthy controls. The differentially expressed cytokines were confirmed by enzyme-linked immunosorbent assay (ELISA) with serum samples from 29 non-relapsed and 35 relapsed MCD patients. The study used the receiver operating characteristic (ROC) curve analysis to investigate the sensitivity and specificity of a serum biomarker for predicting the MCD relapse. Serum IL-12p40 levels increased significantly in the relapsed group. The Area Under the ROC Curve (AUC) of IL-12p40 was 0.727 (95%CI: 0.597–0.856; P < 0.01). The RNA-sequencing analysis and qPCR assay performed on the IL-12 treated mouse podocytes and the control group showed increased expression of podocyte damage genes, such as connective tissue growth factor (CTGF), matrix metallopeptidase 9 (MMP9), secreted phosphoprotein 1 (SPP1), and cyclooxygenase-2 (COX-2) in the former group. IL-12p40 may serve as a new biomarker for predicting the risk of MCD recurrence after glucocorticoid treatment, and it may be involved in the pathogenesis and recurrence of MCD.
登录
查看更多内容
影响因子：
13.6
作者：
Cheng, Huifang;Wang, Suwan;Harris, Raymond C.
通讯作者：
Harris, Raymond C.
影响因子：
19.6
作者：
通讯作者：
--
影响因子：
7
作者：
Bao Y;Bai M;Zhu H;Yuan Y;Wang Y;Zhang Y;Wang J;Xie X;Yao X;Mao J;Fu X;Chen J;Yang Y;Lin W
通讯作者：
Lin W
影响因子：
168.9
作者：
van Vollenhoven, Ronald F.;Hahn, Bevra H.;Rose, Shawn
通讯作者：
Rose, Shawn
影响因子：
4.6
作者：
Matsumoto, K;Kanmatsuse, K
通讯作者：
Kanmatsuse, K